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performed with snaring maneuver as a bailout in cases of coronary ostia impairment
or severe prosthetic leak due to higher deployment for a suboptimal sealing of the
device with valve calcifications (N=2; 28.6%). The majority of accidental embolization
occurred during early experience with the new Accutrak delivery system. In 6 a second
CRS in the correct position was implanted. The misplaced CRS functioned normally,
with no instances of structural deterioration, thrombosis or further distal migration,
and showed complete apposition against the aortic wall. Moreover, no thromboembolic
events were reported in any patient.
Conclusion: CRS embolization can be effectively managed, implanting a second
prosthesis in a standard fashion and leaving the misplaced device in aorta. There seem
to be no long term vascular or neurological adverse events associated with device
embolization or intentional relocation in experienced hands.
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Background: Currently an efficacy of transcatheter aortic valve implantation (TAVI)
has been proved as a less invasive treatment for high risk elderly patients with aortic
stenosis in Europe and United States, and many patients received TAVI. However, there
is no data regarding to appropriate size of aortic valve by TAVI in Asian population
who has smaller build than those in Europe and United states. To clarify aortic annular
size in Japanese patients with aortic stenosis, the following study was evaluated.
Methods: Between May 2004 and December 2008, consecutive 340 patients (male:
158, female: 182) who underwent surgical replacement of aortic valve for aortic
stenosis were studied. Study subjects included tricuspid anatomy in 224 patients and
bicuspid in 116 patients. Because of indication for TAVI, patients with tricuspid
anatomy were evaluated by TTE (transthoracic echocardiography) and TEE
(transesophageal echocardiography). We analyzed the sizes of annulus and implanted
valve.
Results: Patient age was 72.9±8.4 years old (male) and 75.8±6.8 years old (female).
Annulus diameter was 21.1±2.1 mm (male 22.3±1.9 mm, female 20.3±1.9 mm,
p<0.001). The average annulus diameter above 75 years old also had larger size in
male than female (n=42, 22.3±2.0 mm vs n=82, 20.1±1.8 mm). Implanted valve was
smaller than measured annulus both in male (21.7±1.4 mm) and female (19.3±1.3 mm).
Small size valve bellow 20 mm was counted in 31.5% of whole patients, and 46.3%
of female elderly above 75 years old.
Conclusion: Asian population including Japanese shall need a smaller size of
prosthetic aortic valve in elderly. Furthermore, considering the thickness of sewing
ring of tissue valve, Euro-American population may also require a small size valve in
case of value-in-valve technique.
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Background: Transcatheter aortic valve implantation is a therapeutic alternative for
high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of
prosthesis are currently commercialized in France, which can be implanted either via
a transarterial or a transapical approach. The aim of the study was to evaluate in a
national French registry the early safety and efficacy of transcatheter aortic valve
replacement (AVR) using either the Edwards valves or CoreValve in high-surgical-risk
patients with severe aortic stenosis.
Methods: The multicentre national registry was conducted in 33 centres between
January 2010 and July 2011, under the authority of the French Societies of Cardiology
and Thoracic and Cardio-Vascular Surgery. All the valves implanted in France since
the study period were included. The primary endpoint was mortality at 1 month,
6month, 1 year up to 5 year.
Results: Two thousand and five hundred high-surgical-risk patients (logistic
EuroSCORE ≥20%, STS ≥10%, or contra-indication to AVR) were enrolled. Mean age
was 82+7 years and 43.9% were female. Edwards valves and CoreValve were
implanted in 68 and 32% of patients, respectively. The approaches used were
transarterial (transfemoral: 66%; subclavian: 5%) or transapical in 29%. Device success
rate was xx and mortality was xx, xx, xx respectively at 30 days, 6 month and 12
month. Severe complications included stroke (xx), tamponade (xx), acute coronary
occlusion (xx), and vascular complications (xx). Pacemaker was required in xx. At 1
month, xx of patients were in NYHA class II or less, xx at 6 month and xx at 1 year.
All the result will be receive at the end of August 2011
Conclusion: This prospective registry reflects the real-life experience of transcatheter
aortic valve implantation in high-risk elderly patients in France. This registry is the
first exhaustive and consecutive registry included the 2 types of percutaneous aortic
valves
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Background: The percentage of patients eligible for first-generation balloon-
expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, California, USA)
implantation was restricted to definite aortic annulus diameters. Moreover, transfemoral
implantation using this device was limited to patients with large bore iliac-femoral
arteries. This study sought to assess the proportion of patients anatomically suitable
for the current Edwards SAPIEN XT (ES-XT) valve using NovaFlex/E-Sheath delivery
system compared with the past Edwards SAPIEN (ES) valve with RetroFlex 3 delivery
system, including both transfemoral and transapical approaches.
Methods: All high surgical risk patients with severe aortic stenosis referred to our
department as potential candidates for TAVI, underwent transesophageal
echocardiography and angiography of aorta and iliac-femoral arteries in order to assess
anatomical suitability by different approaches. The transfemoral access requirements
for ES/RetroFlex 3 system were a minimal iliofemoral lumen diameter of at least 7
mm for the 22-F/23-mm device and a minimal iliofemoral dimension of at least 8 mm
for the 24-F/26-mm device. The current ES-XT with NovaFlex/E-Sheath delivery
system requires a minimal iliofemoral dimension of at least 6 mm for the 23 mm valve
(NovaFlex 18F/E-Sheath 16F) and 6.5 mm for the 26 mm valve (NovaFlex 19F/ E-
Sheath 18F). The range of annulus diameter considered amenable for implantation was
18-25 mm for the ES valve (23 and 26 mm prosthesis) and 18-27.5 mm for ES-XT
valve (23, 26 and 29 mm prosthesis). Transfemoral approach was considered as the
first option, if not suitable the patient was evaluated for transapical approach.
Results: Data were collected for 293 high-risk patients evaluated for TAVI. Anatomic
suitability was 82% (240/293) for ES RetroFlex versus 95% (277/293) for ES-XT
NovaFlex/E-Sheath. Among 240 patients eligible for ES RetroFlex, 80 (33%) were
suitable for transfemoral implantation, while among 277 patients eligible for ES-XT,
those suitable for tranfemoral approach were 172 (62%).
Conclusion: Using current Edwards devices the percentage of patients suitable for
TAVI increases from 82% to 95%. Moreover, while only 1/3 of patients had anatomic
criteria suitable for the less-invasive transfemoral approach with the previous devices,
with the current Edwards SAPIEN devices this proportion increases to about 2/3 of
patients.
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Background: Although impaired LV function may be considered a contra-indication
for aortic valve replacement, the hemodynamic characteristics of transcatheter valves
may offer procedural and long-term clinical benefit in such patients. We sought to
determine the prevalence of impaired LV systolic function and its impact on the in-
hospital and long-term outcome in patients who underwent Transcatheter Aortic Valve
Implantation (TAVI).
Methods: 230 consecutive patients underwent TAVI with the Medtronic-CoreValve
System. Impaired LV function was defined by LVEF ≤35% (European Multicenter
Study on Operative Risk Stratification and Long-term Outcome in patients with Low-
Flow/Low-Gradient Aortic Stenosis). Study endpoints were defined according to the
Valve Academic Research Consortium recommendations.
Results: Compared to patients with a LVEF >35% (n=197), those with LVEF ≤35%
(n=33) were more often male (78.8 % vs. 46.7%, p<0.001), more symptomatic (NYHA
class III / IV, 97.0% vs. 77.2%, p=0.008) and had a higher prevalence of prior coronary
artery disease (63.6% vs. 43.1%, p=0.029). The Logistic EuroSCORE was 14.8% and
22.8%, respectively (p=0.012). No difference was observed between the 2 groups in
in-hospital or 30-day mortality (3.0% vs. 9.6%, p=0.21), the Combined Safety Endpoint
at 30 days (24.2% and 24.4% p=0.99) and survival free from readmission at 2 years
(61.5% and 59.3%). After adjustment, LVEF ≤ 35% was not associated with an
increased risk of 30-day mortality, in-hospital complications and survival free from
readmission at follow-up.
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Conclusion: The immediate and long-term outcome after TAVI did not differ between
patients with an impaired and preserved LVEF. LVEF ≤35% did not predict adverse
immediate and long-term outcome. These findings indicate that TAVI should not be
withheld in patients with impaired LV function.
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Background: Identifying the optimal fluoroscopic valve projection is important for
successful transcatheter aortic valve replacement (TAVR). We compared angle
predictions from 3-dimensional angiographic reconstructions (3DA) of the aortic root
to those from multidetector computed tomography (MDCT).
Methods: Patients undergoing transfemoral TAVR underwent pre-implant 3DA and
baseline MDCT. Two separate independent operators predicted perpendicular valve
projections for each method prospectively. The angles generated from 3DA and MDCT
as well as the final implant angle were compared to the post deployment perpendicular
valve projection. 3DA reconstructions were generated from a 220 degree rotational
aortic root angiogram during breath hold and rapid ventricular pacing. The shortest
distance from the post deployment perpendicular valve projection to the regression
line of predicted perpendicular valve views were calculated for every patient and
method.
Results: 39 out of 40 patients had adequate image quality for reproducible angle
predictions. There was a significant correlation between 3DA and MDCT for
predictions of perpendicular valve projections (r = 0.682, p<0.001, figure 1). Deviation
from the regression line of predicted angles to the post deployment valve view were
5.1±4.6° for 3DA and 7.9±4.9° for MDCT (p = 0.016). The mean deviation from the
implant angle to the post deployment perpendicular valve view was 1.9±4.6°
RAO/LAO and 5.1±7.2° cranial/caudal.
Conclusion: Both 3DA and MDCT are accurate and safe imaging modalities for
identifying the optimal valve deployment projection in TAVR.
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Background: Patients with severe aortic stenosis (AS) and a history of previous
cardiac surgery who require valvular intervention have an increased peri-operative risk.
Transcatheter aortic valve implantation (TAVI) is increasingly popular in such high-
risk patients. If peripheral vascular disease precludes transfemoral implantation
(TF-TAVI), the transapical approach (TA-TAVI) is used. However this is associated
with pleural disruption and compromise of the left ventricular (LV) continuity. We
sought to evaluate the feasibility of the retrograde, transaortic technique (TAo-TAVI)
using the Edwards SAPIEN valve as an alternative approach avoiding these problems.
Methods: 196 patients with severe aortic stenosis underwent TAVI at St Thomas’
Hospital, London, between January 2008 and March 2011. 59 patients had previously
undergone cardiac surgery and of these 7 patients underwent TAo-TAVI after
considerations of anatomy, risk, LV function and significant respiratory disease. 6 had
previous coronary artery bypass grafting (85.7%) and 1 patient (14.3%) had 2 previous
cardiac operations for resection of subaortic membrane and ventricular septal defect
closure. All patients with CABG had patent grafts including LIMA to LAD and
saphenous vein grafts to native coronaries.
Results: In the TAo-TAVI group the age (mean±SD) was 71.5±13.5 years. 71.4% were
male. Mean logistic EuroScore was 30.4±20.1. Pre-TAVI peak transaortic gradient was
84.6±36.4mmHg and fell to to 13.6±5.7mmHg immediately post-procedure (p=0.002).
All patients underwent successful TAo-TAVI with 23mm (2/6) and 26mm (4/6)
bioprostheses. There were no device related peri-procedural complications. 30-day
mortality was 14.3% (1/7) for TAo-TAVI, 10.0% (3/30)for TA-TAVI and 18.2% (4/22)
for TF-TAVI (p=0.695).
Conclusion: TAo-TAVI is a feasible option in high-risk redo patients with patent
coronary grafts and may provide a preferable access route in these high-risk patients
when TF-TAVI is not possible, avoiding the LV and respiratory complications of TA-
TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) has become an
established treatment for severe aortic stenosis in patients with unacceptable high
surgical risk. Recently, the new AccuTrak delivery system for improved deliverability
of the CoreValve aortic bioprosthesis was launched. It has not been shown yet, if the
new delivery catheter leads to optimized positioning and improved procedural
outcomes.
Methods: We therefore conducted a retrospective single-center analysis comparing
the procedural results after transfemoral CoreValve implantation with or without the
new AccuTrak delivery system.
Results: We evaluated 70 consecutive patients (35 with the original delivery catheter
and 35 with the new AccuTrak catheter) for procedural results after CoreValve
implantation. The use of the AccuTrak delivery catheter resulted in significantly higher
positioning of the CoreValve prosthesis (8.8 mm [7.1 to 11.2 mm] vs. 7.0 mm [5.5 to
9.4 mm]; P= 0.0068) below the annulus (median [interquartile range]). Moreover, the
optimized positioning resulted in reduced rates of significant (≥ grade 2) aortic
regurgitation assessed by postinterventional aortography and echocardiography (P=
0.044 and P=0.0275 respectively). Despite improved positioning, no differences in the
need for permanent pacemaker implantation were observed.
Conclusion: Our retrospective analysis demonstrates improved positioning and
reduced postinterventional aortic regurgitation with the new CoreValve AccuTrak
delivery system. Whether this may also affect the need for permanent pacemaker
insertion or longterm outcome after TAVI needs to be evaluated in larger studies.
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Background: Residual PAR after TAVI is common. However, systematic data on its
severity and its clinical impact are sparse. We, therefore, thought to evaluate incidence,
severity and outcome of residual PAR after TAVI.
Methods: We analyzed data from 167 consecutive TAVI patients treated with either
the Medtronic-CoreValve (n=88) or the Edwards Sapien (n=79) bioprosthesis. PAR
was graded angiographically according to the Sellers criteria at the end of the
procedure.In addition,invasive hemodynamics post implantation(pressure difference:
diastolic aortic pressure – LVEDP (PD DAP–LVEDP)) were analyzed.
Results: TAVI was technically successful in all patients with overall mortality rates of
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